Trifluoroacetic acid → Trifluoroacetic acid

HRID 85611Notes

Reaction equation

HRID 85611 reaction equation
[F:1][C:2]1[CH:7]=[C:6]([CH2:8][NH:9][C@:10]23[CH2:45][CH2:44][C@@H:43]([C:46]([CH3:48])=[CH2:47])[C@@H:11]2[C@@H:12]2[C@@:25]([CH3:28])([CH2:26][CH2:27]3)[C@@:24]3([CH3:29])[C@@H:15]([C@:16]4([CH3:42])[C@@H:21]([CH2:22][CH2:23]3)[C:20]([CH3:31])([CH3:30])[C:19]([C:32]3[CH:41]=[CH:40][C:35]([C:36]([O:38]C)=[O:37])=[CH:34][CH:33]=3)=[CH:18][CH2:17]4)[CH2:14][CH2:13]2)[CH:5]=[CH:4][N:3]=1.[C:49]([OH:55])([C:51]([F:54])([F:53])[F:52])=[O:50].O[Li].O>C1COCC1>[F:1][C:2]1[CH:7]=[C:6]([CH2:8][NH:9][C@:10]23[CH2:45][CH2:44][C@@H:43]([C:46]([CH3:48])=[CH2:47])[C@@H:11]2[C@@H:12]2[C@@:25]([CH3:28])([CH2:26][CH2:27]3)[C@@:24]3([CH3:29])[C@@H:15]([C@:16]4([CH3:42])[C@@H:21]([CH2:22][CH2:23]3)[C:20]([CH3:31])([CH3:30])[C:19]([C:32]3[CH:41]=[CH:40][C:35]([C:36]([OH:38])=[O:37])=[CH:34][CH:33]=3)=[CH:18][CH2:17]4)[CH2:14][CH2:13]2)[CH:5]=[CH:4][N:3]=1.[C:49]([OH:55])([C:51]([F:54])([F:53])[F:52])=[O:50]

Participants

6

Conditions

Temperature
75 °C

Procedure

To a solution of methyl 4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-((2-fluoropyridin-4-yl)methylamino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoate, TFA (77.7 mg, 0.101 mmol) in THF (3 mL) was added a 0.753 molar aqueous solution of LiOH.H2O (0.539 mL, 0.405 mmol). The reaction mixture was heated to 75° C. After 4 h, the reaction mixture was concentrated. The crude residue was dissolved in THF (1.5 mL) and MeOH (200 μL), filtered and purified by reverse phase preparative HPLC using HPLC method 3 to give 4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-((2-fluoropyridin-4-yl)methylamino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoic acid, TFA (30.6 mg, 0.037 mmol, 36.1% yield) as a white solid. LCMS: m/e 637.7 (M−H)−, 3.12 min (method 6). 1H NMR (500 MHz, 1:1 CDCl3:MeOD) δ=8.24 (d, J=5.2 Hz, 1H), 7.92 (d, J=8.2 Hz, 2H), 7.43 (d, J=5.2 Hz, 1H), 7.24 (s, 1H), 7.20 (d, J=8.5 Hz, 2H), 5.29 (dd, J=1.7, 6.3 Hz, 1H), 4.78 (s, 1H), 4.17 (br. s., 2H), 2.78-2.69 (m, 1H), 2.18-2.10 (m, 2H), 2.09-2.01 (m, 2H), 1.98 (dd, J=3.1, 11.9 Hz, 1H), 1.96-1.88 (m, 1H), 1.83-1.76 (m, 1H), 1.72 (s, 3H), 1.70-1.64 (m, 1H), 1.63-1.40 (m, 10H), 1.39-1.31 (m, 1H), 1.31-1.23 (m, 2H), 1.13 (s, 3H), 1.07 (s, 3H), 1.02 (s, 3H), 0.95 (s, 3H), 0.94 (s, 3H). 13C NMR (1:1 CDCl3:MeOD) d ppm 15.3, 16.6, 17.4, 19.5, 20.6, 21.8, 22.2, 26.1, 27.6, 29.0, 29.5, 30.2, 33.9, 34.6, 37.2, 38.2, 38.4, 41.8, 42.8, 43.1, 45.7, 47.2, 49.7, 49.9, 50.3, 50.5, 53.9, 78.8, 123.1, 123.2, 124.9, 129.3, 129.7, 131.0, 147.4, 149.7, 164.0, 166.0, 170.1.

Workup

  1. concentrationthe reaction mixture was concentrated
  2. dissolutionThe crude residue was dissolved in THF (1.5 mL)
  3. filtrationMeOH (200 μL), filtered
  4. custompurified by reverse phase preparative HPLC

Sources & evidence

ORD record
ord-09171b72b3554738bf5b0a7ea46aac0b
Source dataset
uspto-grants-2014_09
Patent number
US08846647B2

Reaction notes

Loading…